• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, August 12, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

University of Birmingham develops sight-saving treatment for eye infection or trauma

Bioengineer by Bioengineer
December 21, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Scientists at the University of Birmingham have developed a novel eye drop that rapidly reduces sight-threatening scarring to the surface of the eye.

The surface of the eye (the cornea) is usually transparent, but scars resulting from eye infection or trauma make it opaque causing blurred vision or in extreme cases complete blindness.

Their pre-clinical research, published today (Friday 21 December 2018) in npj Regenerative Medicine, shows that within a matter of days the eye drop speeds healing, reduces scarring and improves corneal transparency compared to the current standard of care for Pseudomonas aeruginosa, an eye infection commonly associated with poor contact lens hygiene.

The current standard of care for eye infection are eye drops containing antibiotics and corticosteroids to reduce inflammation, followed by intensive lubrication to prevent further damage to the eye during blinking. These treatments effectively sterilize the eye, although some patients are left with visual ‘hazing’ due to scars on the cornea.

The only option to correct this is costly and cumbersome surgical interventions, such as corneal transplants, which are fraught with risks of failure or rejection.

The Birmingham scientists, led by Professor Liam Grover from the University’s School of Chemical Engineering and Professor Ann Logan from the University’s Institute of Inflammation and Ageing, have developed the eye drop which consists of a fluid gel loaded with a natural wound-healing protein called Decorin.

Professor Ann Logan said: “This innovative fluid gel in the eye drop is designed to retain the Decorin on the surface of the eye, and form a ‘therapeutic bandage’ that promotes scarless healing.”

Professor Liam Grover explained: “The fluid gel is a novel material that can transition between a solid and liquid state. This means it contours itself to the surface of the eye, is retained there, and is only slowly removed by blinking.”

This research has shown for the first time that the fluid gel has a therapeutic effect in its own right, and the researchers believe it forms a protective barrier that protects the surface of the eye from further damage caused by blinking. The fluid gel has been patented by University of Birmingham Enterprise.

Dr Richard Moakes, also from the School of Chemical Engineering explained: “We are now continuing our work to test and refine the formulation for this novel anti-scarring eye ‘bandage’.”

Dr Lisa Hill, from the University’s Institute of Clinical Sciences, said: “The anti-scarring eye drop has the potential to vastly improve outcomes for patients with eye infection and trauma. It could also help save many people’s sight, particularly in the developing world where surgical interventions such as corneal transplants are not available.”

###

Media Contact
Beck Lockwood
[email protected]
http://dx.doi.org/10.1038/s41536-018-0061-4

Tags: BiotechnologyMedicine/HealthTrauma/Injury
Share12Tweet8Share2ShareShareShare2

Related Posts

How Cellular Senescence and Immunity Drive Cancer, With Insights for Glioblastoma

August 12, 2026

Ovarian Cancer Grows in Omentum Independently of Mature Fat Cells

August 12, 2026

Nearly All Tested Personal Care and Cleaning Products Contain Unlabeled Chemicals

August 12, 2026

Molecular Clues Reveal Why Neuromas Cause Pain

August 12, 2026
Please login to join discussion

POPULAR NEWS

  • How Cellular Senescence and Immunity Drive Cancer, With Insights for Glioblastoma

    29 shares
    Share 12 Tweet 7
  • Bifidobacterium Synbiotic Found Safe and Well-Tolerated, May Improve Digestion in Young Children

    29 shares
    Share 12 Tweet 7
  • Ovarian Cancer Grows in Omentum Independently of Mature Fat Cells

    29 shares
    Share 12 Tweet 7
  • Cement Plants Could Help Remove COâ‚‚ From the Atmosphere

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

How Cellular Senescence and Immunity Drive Cancer, With Insights for Glioblastoma

Bifidobacterium Synbiotic Found Safe and Well-Tolerated, May Improve Digestion in Young Children

Ovarian Cancer Grows in Omentum Independently of Mature Fat Cells

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.